As anticipated in the title, this contribution is basically divided into two, strictly connected,
parts. The first is a personal overview of the ruthenium drug candidate NAMI‐A, almost 30 …

The promising drug candidate indazolium trans‐[tetrachlorobis (1H‐indazole) ruthenate
(III)](KP1019) is the second Ru‐based anticancer agent to enter clinical trials. In this review …

Indazolium trans-[tetrachlorobis (1H-indazole) ruthenate (III)](KP1019 or FFC14A) is just the
second ruthenium-based anticancer agent after NAMI-A which was developed to the stage …

The mortality rates from various tumor types can be reduced dramatically by use of highly
active drugs. This is particularly true for platinum-based drugs, being among the most …

Ruthenium‐based anticancer chemotherapies are making significant advances in clinical
trials. Until recently, the focus has been on coordination complexes, and mechanisms such …

Inductively Coupled Plasma-Mass Spectrometry presents a concise AZ description of
inductively coupled plasma-mass spectrometry, written in layman's terms, for use in the …

A full understanding of the modes of action of the metal-based antitumoral drugs requires
the study of their interactions with all possible biological targets, including aminoacids …

A critical discussion is presented about the possible role of Pt–protein interactions in the
mechanisms of action of platinum anticancer compounds. Although, since 40 years from its …

The state-of-the-art of species-selective analysis for trace metals and metalloids in biological
materials by chromatographic and electrophoretic separation techniques with element …

Metal-based compounds form a promising class of therapeutic agents, whose mechanisms
of action still need to be elucidated, and that are in general prone to undergo extensive …